Skip to main content

Table 4 Biomarkers and in-hospital mortality

From: Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study

 

Survivors ( N  = 83)

Non-survivors ( N  = 15)

P -value

Plasma NGAL (ng/ml)

111 (60 to 282)

269 (91 to 583)

0.03

Plasma IL-6 (pg/ml)

78.2 (25.1 to 545.5)

342.7 (48.3 to 924.0)

0.06

Plasma EPO (mIU/ml)

17.1 (9.8 to 36.9)

33.6 (10.4 to 88.7)

0.21

Serum creatinine (mg/dl)

0.83 (0.61 to 1.41)

1.04 (0.75 to 2.42)

0.19

Urinary TIMP-2 (ng/ml)

2.8 (0.9 to 6.9)

11.4 (3.8 to 65.7)

0.004

Urinary NAG (U/L)

11.9 (3.5 to 24.9)

33.0 (13.4 to 51.1)

0.01

  1. EPO, Erythropoietin; IL, Interleukin; NAG, N-acetyl-β-d-glucosaminidase; NGAL, Neutrophil gelatinase-associated lipocalin; TIMP-2, Tissue inhibitor of matrix metalloproteinase-2.